ArticleRedox biology2026
Comparative analysis of myeloperoxidase deficiency in humans and mice: Conserved and species-specific effects on neutrophil biology.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyeloperoxidase (MPO), a heme-containing enzyme released by activated polymorphonuclear neutrophils (PMNs) represents a key mediator of inflammation-driven cardiovascular disease, positioning MPO as a promising therapeutic target. However, substantial interspecies differences between murine and human neutrophil biology challenge the translation of preclinical findings from rodent studies into patients.
methods11,608 patients were screened for MPO deficiency using the ADVIA 2120i system. 282 individuals exhibited a reduced MPO activity. 56 patients were eligible, consented to be enrolled and were compared to 20 control patients. MPO levels and activity were measured by enzyme-linked immunosorbent assay (ELISA), immunoblotting, a tetramethylbenzidin (TMB)-based peroxidase and nitric oxide (NO)-consumption assay. For cross-species analysis, shotgun proteomics, Gene Ontology (GO) and REACTOME pathway enrichment analyses were conducted on bone marrow derived PMNs from Mpo
resultsPatients with persistent (MPO
conclusionMPO deficiency leads to broadly conserved alterations in neutrophil immune and stress responses across humans and mice. However, similar functional outcomes may involve different signaling pathways in each species contributing to divergent phenotypes in disease models. These findings underscore species-specific mechanisms in MPO-related neutrophil biology and highlight critical considerations for translating MPO-targeted therapies from animal models to human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.